Alexis R Harvey1, Sridhar V Basavaraju1, Koo-Whang Chung1, Matthew J Kuehnert1. 1. Office of Blood, Organ and Other Tissue Safety, Division of Healthcare Quality Promotion, National Center for Emerging, Zoonotic, and Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: In 2010, health care facilities in the United States began voluntary enrollment in the National Healthcare Safety Network (NHSN) Hemovigilance Module. Participants report transfusion practices; red blood cell, platelet (PLT), plasma, and cryoprecipitate units transfused; and transfusion-related adverse reactions and process errors to the Centers for Disease Control and Prevention through a secure, Internet-accessible surveillance application available to transfusing facilities. STUDY DESIGN AND METHODS: Facilities submitting at least 1 month of transfused components data and adverse reactions from January 1, 2010, to December 31, 2012, were included in this analysis. Adverse reaction rates for transfused components, stratified by component type and collection and modification methods, were calculated. RESULTS: In 2010 to 2012, a total of 77 facilities reported 5136 adverse reactions among 2,144,723 components transfused (239.5/100,000). Allergic (46.8%) and febrile nonhemolytic (36.1%) reactions were most frequent; 7.2% of all reactions were severe or life-threatening and 0.1% were fatal. PLT transfusions (421.7/100,000) had the highest adverse reaction rate. CONCLUSION: Adverse transfusion reaction rates from the NHSN Hemovigilance Module in the United States are comparable to early hemovigilance reporting from other countries. Although severe reactions are infrequent, the numbers of transfusion reactions in US hospitals suggest that interventions to prevent these reactions are important for patient safety. Further investigation is needed to understand the apparent increased risk of reactions from apheresis-derived blood components. Comprehensive evaluation, including data validation, is important to continued refinement of the module. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND: In 2010, health care facilities in the United States began voluntary enrollment in the National Healthcare Safety Network (NHSN) Hemovigilance Module. Participants report transfusion practices; red blood cell, platelet (PLT), plasma, and cryoprecipitate units transfused; and transfusion-related adverse reactions and process errors to the Centers for Disease Control and Prevention through a secure, Internet-accessible surveillance application available to transfusing facilities. STUDY DESIGN AND METHODS: Facilities submitting at least 1 month of transfused components data and adverse reactions from January 1, 2010, to December 31, 2012, were included in this analysis. Adverse reaction rates for transfused components, stratified by component type and collection and modification methods, were calculated. RESULTS: In 2010 to 2012, a total of 77 facilities reported 5136 adverse reactions among 2,144,723 components transfused (239.5/100,000). Allergic (46.8%) and febrile nonhemolytic (36.1%) reactions were most frequent; 7.2% of all reactions were severe or life-threatening and 0.1% were fatal. PLT transfusions (421.7/100,000) had the highest adverse reaction rate. CONCLUSION: Adverse transfusion reaction rates from the NHSN Hemovigilance Module in the United States are comparable to early hemovigilance reporting from other countries. Although severe reactions are infrequent, the numbers of transfusion reactions in US hospitals suggest that interventions to prevent these reactions are important for patient safety. Further investigation is needed to understand the apparent increased risk of reactions from apheresis-derived blood components. Comprehensive evaluation, including data validation, is important to continued refinement of the module. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Lauren A Backman; Gayle Nobert; Richard Melchreit; Renee Fekieta; Louise M Dembry Journal: Am J Infect Control Date: 2013-10-29 Impact factor: 2.918
Authors: Aaron A R Tobian; Alice K Fuller; Kristin Uglik; Daniel J Tisch; Prabhakar D Borge; Richard J Benjamin; Paul M Ness; Karen E King Journal: Transfusion Date: 2013-11-19 Impact factor: 3.157
Authors: Luswa Lukwago; Miriam Nanyunja; Nestor Ndayimirije; Joseph Wamala; Mugaga Malimbo; William Mbabazi; Anne Gasasira; Immaculate N Nabukenya; Monica Musenero; Wondimagegnehu Alemu; Helen Perry; Peter Nsubuga; Ambrose Talisuna Journal: Health Policy Plan Date: 2012-06-04 Impact factor: 3.344
Authors: Sanjida J Mowla; Ian T Kracalik; Mathew R P Sapiano; Lynne O'Hearn; Chester Andrzejewski; Sridhar V Basavaraju Journal: Transfus Med Rev Date: 2021-04-02
Authors: Chris Edens; Kathryn A Haass; Melissa Cumming; Anthony Osinski; Lynne O'Hearn; Kelly Passanisi; Lynn Eaton; Paul Visintainer; Alexandra Savinkina; Matthew J Kuehnert; Sridhar V Basavaraju; Chester Andrzejewski Journal: Transfusion Date: 2018-11-14 Impact factor: 3.157
Authors: Mathew R P Sapiano; Alexandra A Savinkina; Katherine D Ellingson; Kathryn A Haass; Misha L Baker; Richard A Henry; James J Berger; Matthew J Kuehnert; Sridhar V Basavaraju Journal: Transfusion Date: 2017-06 Impact factor: 3.157
Authors: Katherine D Ellingson; Mathew R P Sapiano; Kathryn A Haass; Alexandra A Savinkina; Misha L Baker; Koo-Whang Chung; Richard A Henry; James J Berger; Matthew J Kuehnert; Sridhar V Basavaraju Journal: Transfusion Date: 2017-06 Impact factor: 3.157